A three-dimensional star-shaped α-helix polypeptide having a high-efficiency gene delivery capability, and a preparation method and an application thereof. A dendrimer is used as an initiator and dichloromethane is used as a reaction solvent to initiate high-speed ring-opening polymerization of different types of N-carboxylic anhydride monomers, and groups having different electrical properties are introduced at the ends via click chemistry reactions. The abundant amino groups on the surface of the dendrimer provide enough polymerization sites to enable the polypeptide to form a three-dimensional spherical topological structure, and the topological structure provides an opportunity for initial acceleration of the ring-opening polymerization reaction. The higher positive charge density caused by polypeptide side chain modified guanidine/amino groups etc. achieves a high-efficiency gene loading capability by the electrostatic effect between positive and negative charges, and the α-helix rigid structure on the secondary structure thus enables the polypeptide to have stronger membrane penetration capability.

Lipid nanoparticles having improved properties are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent to primates for treatment of various indications is also described.

Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a β-catenin inhibitor and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a β-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a β-catenin inhibitor, such as a β-catenin nucleic acid inhibitor molecule.

Nanostructure lipid carriers, delivery systems, methods of making nanostructured lipid carriers and delivery systems, and methods of using the same are disclosed. A composition is disclosed and comprises at least one nanostructured lipid carrier, the nanostructured lipid carrier comprising a shell comprising an emulsifier, and an inner matrix comprising a solid lipid and a liquid lipid, wherein the nanostructured lipid carrier has a diameter of 50 nm or less.

Improved RNA interference (RNAi) efficiency in insects is disclosed herein. In particular, certain embodiments of the presently-disclosed subject matter relate to use of nanoformulations of double-stranded RNA (dsRNA) to limit nuclease degradation of the dsRNA, and enhance cellular update and intracellular transport to improve delivery of the dsRNA to enhance RNAi in insects.

Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Nanoparticle compositions for delivery of nucleic acids to subjects including carriers comprising sugar functionalized nucleic acid carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the delivery molecules are described. Methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects are provided.

Metastatic triple negative breast cancer (TNBC) still carries a dismal prognosis with the current treatment paradigms. The effectiveness of drug treatment for many solid tumors such as TNBC is limited by tumor heterogeneity, lack of tumor specificity, off-target toxicities, and transient therapeutic action(s). Strategies that provide tumor-specific, sustained concentrations of drugs to the tumors and tumor receptor-specific binding, while reducing off-target effects are needed to ensure sufficient tumor cell uptake within the primary and metastatic tumor microenvironment. The decreased non-specific adhesivity, receptor-targeted nanoparticle formulations (“DART” nanoparticles) of the invention were assessed for clinical potential in directing biological agents to the cell surface receptor Fn14, which is expressed in many solid cancer types, including TNBC primary tumors and metastatic lesions. They are contemplated for use against solid tumors, particularly brain tumors such as glioblastoma and breast cancer, including metastatic breast cancer.

The present invention relates to a composition for use in the treatment of onychomycosis and/or tinea pedis, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an infected area in the range of about 5 μg to about 50 μg of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and/or inter-digital spaces and/or front of the foot.

The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.